NCT04221438 2026-04-01
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
Phase 2 Terminated
Clinical Trials
16 trialsNCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT04585815 2026-01-09
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
Phase 1/2 Terminated
NCT05743036 2025-08-08
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Terminated
NCT05097599 2025-01-08
StrataPATH
Strata Oncology
Phase 2 Terminated
NCT03973918 2024-10-31
BRAF
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT04800822 2024-10-22
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT04655157 2024-05-23
QUAD01
University of Pittsburgh
Phase 1/2 Terminated
NCT04390243 2024-05-06
Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
Academic and Community Cancer Research United
Phase 2 Terminated
NCT03911869 2023-05-31
POLARIS
Pfizer
Phase 2 Terminated
NCT04801966 2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA Terminated
NCT03878719 2023-04-03
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
Pfizer
Phase 1 Terminated
NCT04044430 2023-01-09
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
University of California, San Francisco
Phase 1 Terminated
NCT01981187 2021-03-26
SIGNATURE
Pfizer
Phase 2 Terminated
NCT01820364 2017-01-09
LOGIC
Array BioPharma
Phase 2 Terminated
NCT01777776 2016-09-13
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Array BioPharma
Phase 1/2 Terminated